Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-Current DebtShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Gains from Investment Securities: 2014-2025

Historic Gains from Investment Securities for Ascendis Pharma A (ASND) over the last 12 years, with Sep 2025 value amounting to -$2.5 million.

  • Ascendis Pharma A's Gains from Investment Securities fell 1378.10% to -$2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.5 million, marking a year-over-year decrease of 35.58%. This contributed to the annual value of -$6.0 million for FY2024, which is 24.16% down from last year.
  • According to the latest figures from Q3 2025, Ascendis Pharma A's Gains from Investment Securities is -$2.5 million, which was up 44.76% from -$4.6 million recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Gains from Investment Securities ranged from a high of $1.6 million in Q4 2022 and a low of -$4.6 million during Q2 2025.
  • For the 3-year period, Ascendis Pharma A's Gains from Investment Securities averaged around -$1.6 million, with its median value being -$1.1 million (2023).
  • Per our database at Business Quant, Ascendis Pharma A's Gains from Investment Securities spiked by 282.58% in 2022 and then tumbled by 1,378.10% in 2025.
  • Ascendis Pharma A's Gains from Investment Securities (Quarterly) stood at $410,686 in 2021, then surged by 282.58% to $1.6 million in 2022, then plummeted by 314.34% to -$3.4 million in 2023, then spiked by 32.19% to -$2.3 million in 2024, then slumped by 1,378.10% to -$2.5 million in 2025.
  • Its Gains from Investment Securities was -$2.5 million in Q3 2025, compared to -$4.6 million in Q2 2025 and -$54,698 in Q1 2025.